LSTA: Lisata Therapeutics, Inc. - Summary | Jitta

Lisata Therapeutics, Inc.

NASDAQ:LSTA

Price
$3.52
Loss Chance
57.9%
1.07JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
155 / 279
504 / 713
3,494 / 4,223
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (10)
Recent Business Performance (17)
Financial Strength (23)
Return to Shareholders (0)
Competitive Advantage (12)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
Cash Conversion CycleLess than 30 days
Operating MarginDeclined
New Share IssuedMore than 50% in 5 years
CapExVery High
Key Stats
Jitta Score
Jitta Line
1.07
100.00%
2.21
135.20%
3.05
148.34%
Biotechnology
5.68
35.16%
5.68
35.16%
6.36
42.63%
COMPANY DESCRIPTION
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.